Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3052, Australia.
Murdoch Children's Research Institute, Royal Children's Hospital and Department of Paediatrics, University of Melbourne, Parkville, Victoria 3052, Australia.
Open Biol. 2022 Dec;12(12):220274. doi: 10.1098/rsob.220274. Epub 2022 Dec 7.
Mitochondrial diseases are a broad, genetically heterogeneous class of metabolic disorders characterized by deficits in oxidative phosphorylation (OXPHOS). Primary mitochondrial disease (PMD) defines pathologies resulting from mutation of mitochondrial DNA (mtDNA) or nuclear genes affecting either mtDNA expression or the biogenesis and function of the respiratory chain. Secondary mitochondrial disease (SMD) arises due to mutation of nuclear-encoded genes independent of, or indirectly influencing OXPHOS assembly and operation. Despite instances of novel SMD increasing year-on-year, PMD is much more widely discussed in the literature. Indeed, since the implementation of next generation sequencing (NGS) techniques in 2010, many novel mitochondrial disease genes have been identified, approximately half of which are linked to SMD. This review will consolidate existing knowledge of SMDs and outline discrete categories within which to better understand the diversity of SMD phenotypes. By providing context to the biochemical and molecular pathways perturbed in SMD, we hope to further demonstrate the intricacies of SMD pathologies outside of their indirect contribution to mitochondrial energy generation.
线粒体疾病是一类广泛的、具有遗传异质性的代谢紊乱疾病,其特征是氧化磷酸化(OXPHOS)缺陷。原发性线粒体疾病(PMD)定义为由线粒体 DNA(mtDNA)突变或影响 mtDNA 表达或呼吸链生物发生和功能的核基因突变引起的病理学。继发性线粒体疾病(SMD)是由于核编码基因突变引起的,与 OXPHOS 组装和运行无关或间接影响。尽管每年都有新的 SMD 病例增加,但文献中更多地讨论 PMD。事实上,自 2010 年新一代测序(NGS)技术实施以来,已经发现了许多新的线粒体疾病基因,其中约一半与 SMD 有关。本综述将整合现有的 SMD 知识,并概述离散类别,以更好地理解 SMD 表型的多样性。通过提供 SMD 中受干扰的生化和分子途径的背景,我们希望进一步展示 SMD 病理学的复杂性,而不仅仅是其对线粒体能量产生的间接贡献。